Echo Therapeutics has sent a presubmission package to the FDA for its Symphony Continuous Glucose Monitoring System to be used in critical care settings. The move represents a significant first step toward the company's effort to bring the device to the U.S. market, CEO Patrick Mooney said.

Related Summaries